Combined doxorubicin and arctigenin treatment induce cell cycle arrest‐associated cell death by promoting doxorubicin uptake in doxorubicin‐resistant breast cancer cells
- 26 July 2023
- journal article
- research article
- Published by Wiley in IUBMB Life
- Vol. 75 (9) , 765-777
Abstract
Chemotherapy failure is often caused by drug resistance, for which no effective treatment strategy has been established. Many studies have been undertaken with the aim of overcoming drug resistance using natural products. Arctigenin (ATG), a natural product, has been investigated for its anti‐cancer effects in HER2‐overexpressing, ER‐positive, and triple‐negative breast cancer cells. We investigated the efficacy of ATG against self‐established doxorubicin (DOX)‐resistant breast cancer cells (MCF‐DR and MDA‐DR cells) derived from MCF‐7 and MDA‐MB‐231 cells, respectively. ATG was found to increase DOX intracellular levels by downregulating multidrug Resistance 1 (MDR1) mRNA expression in DOX‐resistant cells. In addition, combined treatment with DOX and ATG (DOX/ATG) reduced the viability of and colony formation by DOX‐resistant cells. DOX/ATG also significantly induced G2/M cell cycle arrest by suppressing the Cyclin D1/CDK4/RB pathways and suppressed the expressions of MDR1 and Cyclin D1 by inhibiting the Mitogen‐activated protein kinase (MAPK)/Activating protein‐1 (AP‐1) signaling pathways. Furthermore, DOX/ATG induced DNA damage and attenuated the expressions of RAD51 and Ku80. However, PARP1 (Poly [ADP‐ribose] polymerase1) cleavage and AIF (Apoptosis‐inducing factor) induced apoptosis did not occur despite DNA damage‐induced cell death. Rather, flow cytometry showed that DOX/ATG caused necrosis. In summary, DOX/ATG increased intracellular DOX levels by inhibiting MDR1 and inducing G2/M arrest by inhibiting the Cyclin D1/CDK4/RB pathways and causing necrosis by damaging DNA. Our results suggest that ATG might be used as an adjuvant to enhance the efficacy of DOX in DOX‐resistant breast cancer.Keywords
Funding Information
- Ministry of Education (2020R1A6A3A01100376)
- Ministry of Science and ICT, South Korea (2022R1A2C1013203)
This publication has 39 references indexed in Scilit:
- Doxorubicin, DNA torsion, and chromatin dynamicsBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2014
- Differential Regulation of c-Jun Protein Plays an Instrumental Role in Chemoresistance of Cancer CellsJournal of Biological Chemistry, 2013
- Doxorubicin pathwaysPharmacogenetics and Genomics, 2011
- The elements of human cyclin D1 promoter and regulation involvedClinical Epigenetics, 2011
- γH2AX: a sensitive molecular marker of DNA damage and repairLeukemia, 2010
- Doxorubicin Exerts Cytotoxic Effects through Cell Cycle Arrest and Fas-Mediated Cell DeathPharmacology, 2009
- Cyclin D1 Degradation Is Sufficient to Induce G1 Cell Cycle Arrest despite Constitutive Expression of Cyclin E2 in Ovarian Cancer CellsCancer Research, 2009
- Centrosome-associated regulators of the G2/M checkpoint as targets for cancer therapyMolecular Cancer, 2009
- Quantitation of Doxorubicin Uptake, Efflux, and Modulation of Multidrug Resistance (MDR) in MDR Human Cancer CellsThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Mechanisms of cytochrome c release from mitochondriaCell Death & Differentiation, 2006